Oxford Biomedica - OXB Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: GBX 433.33
  • Forecasted Upside: 9.37%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 396.21
▲ +1.21 (0.31%)

This chart shows the closing price for OXB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oxford Biomedica Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OXB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OXB

Analyst Price Target is GBX 433.33
▲ +9.37% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Oxford Biomedica in the last 3 months. The average price target is GBX 433.33, with a high forecast of GBX 740 and a low forecast of GBX 180. The average price target represents a 9.37% upside from the last price of GBX 396.21.

This chart shows the closing price for OXB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 investment analysts is to hold stock in Oxford Biomedica. This rating has held steady since September 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/19/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/17/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/17/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/15/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/13/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/12/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/11/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/24/2024Deutsche Bank AktiengesellschaftBoost TargetHoldGBX 250 ➝ GBX 380
5/21/2024Royal Bank of CanadaReiterated RatingOutperformGBX 740
3/20/2024Numis SecuritiesReiterated RatingHoldGBX 180
9/26/2023Liberum CapitalLower TargetHoldGBX 350 ➝ GBX 310
6/21/2023JPMorgan Chase & Co.Reiterated RatingNeutralGBX 495
5/24/2023Royal Bank of CanadaLower TargetOutperformGBX 1,110 ➝ GBX 1,010
10/11/2022Royal Bank of CanadaBoost TargetOutperformGBX 1,020 ➝ GBX 1,110
6/30/2022Royal Bank of CanadaReiterated RatingOutperformGBX 1,070
6/21/2022Royal Bank of CanadaReiterated RatingOutperformGBX 1,070
5/23/2022Royal Bank of CanadaReiterated RatingOutperformGBX 1,070
4/20/2022Liberum CapitalReiterated RatingBuyGBX 1,380
3/24/2022Royal Bank of CanadaReiterated RatingOutperformGBX 1,340
2/1/2022Royal Bank of CanadaLower TargetOutperformGBX 1,450 ➝ GBX 1,340
10/19/2021Peel HuntReiterated RatingBuyGBX 2,150
10/19/2021Peel HuntReiterated RatingBuyGBX 2,150
5/19/2021Liberum CapitalBoost TargetBuyGBX 1,300 ➝ GBX 1,330
5/18/2021Peel HuntReiterated RatingBuyGBX 1,150
5/18/2021Peel HuntReiterated RatingBuyGBX 1,150
5/18/2021Numis SecuritiesReiterated RatingBuyGBX 1,200
4/15/2021Liberum CapitalReiterated RatingBuyGBX 1,300 ➝ GBX 1,280
4/6/2021Liberum CapitalReiterated RatingBuyGBX 1,280
8/3/2020Liberum CapitalReiterated RatingBuy
7/31/2020Peel HuntReiterated RatingBuy
7/21/2020Peel HuntReiterated RatingBuy
7/21/2020Liberum CapitalReiterated RatingBuy
7/2/2020Peel HuntReiterated RatingBuy
6/24/2020Liberum CapitalLower TargetBuyGBX 1,090 ➝ GBX 1,050
6/19/2020Peel HuntReiterated RatingBuyGBX 1,050 ➝ GBX 1,000
6/8/2020Peel HuntReiterated RatingBuyGBX 1,060 ➝ GBX 1,050
6/8/2020Liberum CapitalReiterated RatingBuy
6/1/2020Peel HuntReiterated RatingBuy
5/29/2020Liberum CapitalReiterated RatingBuy
5/14/2020Jefferies Financial GroupBoost TargetHoldGBX 700 ➝ GBX 730
5/13/2020Peel HuntReiterated RatingBuy
5/13/2020Liberum CapitalReiterated RatingBuy
5/6/2020Liberum CapitalReiterated RatingBuy
5/1/2020Peel HuntReiterated RatingBuy
4/28/2020Liberum CapitalBoost TargetBuyGBX 860 ➝ GBX 1,090
4/24/2020Peel HuntReiterated RatingBuy
4/8/2020Liberum CapitalReiterated RatingBuy
4/7/2020Peel HuntReiterated RatingBuy
3/18/2020Peel HuntReiterated RatingBuy
3/18/2020Liberum CapitalReiterated RatingBuy
3/5/2020Peel HuntReiterated RatingBuy
2/13/2020Peel HuntReiterated RatingBuy
(Data available from 2/12/2020 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/17/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/16/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/15/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/15/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/14/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/14/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/13/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/12/2025

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Oxford Biomedica logo
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.
Read More

Today's Range

Now: GBX 396.21
Low: 394
High: 403

50 Day Range

MA: GBX 417.59
Low: 392
High: 444

52 Week Range

Now: GBX 396.21
Low: 167
High: 455

Volume

20,519 shs

Average Volume

165,994 shs

Market Capitalization

£417.45 million

P/E Ratio

N/A

Dividend Yield

4.57%

Beta

1.09

Frequently Asked Questions

What sell-side analysts currently cover shares of Oxford Biomedica?

The following Wall Street research analysts have issued stock ratings on Oxford Biomedica in the last year: Deutsche Bank Aktiengesellschaft, Numis Securities Ltd, and Royal Bank of Canada.
View the latest analyst ratings for OXB.

What is the current price target for Oxford Biomedica?

0 Wall Street analysts have set twelve-month price targets for Oxford Biomedica in the last year. Their average twelve-month price target is GBX 433.33, suggesting a possible upside of 9.4%. Royal Bank of Canada has the highest price target set, predicting OXB will reach GBX 740 in the next twelve months. Numis Securities Ltd has the lowest price target set, forecasting a price of GBX 180 for Oxford Biomedica in the next year.
View the latest price targets for OXB.

What is the current consensus analyst rating for Oxford Biomedica?

Oxford Biomedica currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OXB, but not buy more shares or sell existing shares.
View the latest ratings for OXB.

What other companies compete with Oxford Biomedica?

How do I contact Oxford Biomedica's investor relations team?

Oxford Biomedica's physical mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The biopharmaceutical company's listed phone number is +44-1865-783000. The official website for Oxford Biomedica is www.oxfordbiomedica.co.uk. Learn More about contacing Oxford Biomedica investor relations.